BACKGROUND AND PURPOSE: The prognosis of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) is generally poor. However, prognostic factors can help optimize the care for the individual patient. This study investigated potential prognostic factors, including HPV status, for locoregional control (LRC), metastases-free survival (MFS), and survival (OS). PATIENTS AND METHODS: Twelve potential prognostic factors were investigated in 170 patients irradiated for stage III or IV SCCHN, including age (≤ 60 vs > 60 years), gender, ECOG performance score (0-1 vs 2), preradiotherapy hemoglobin level (< 12 vs ≥ 12 g/dl), tumor site (oropharynx, oral cavity, hypopharynx, or larynx), histological grade (G1-2 vs G3), T category (T1-T2 vs T3-T4), N category (N0-N1 vs N2-N3), AJCC stage (III vs IV), surgery (no vs yes), and chemotherapy (no vs yes). RESULTS: On multivariate analysis, positive HPV status (RR 2.34; p = 0.014), ECOG performance score 0-1 (RR 1.94; p = 0.017), preRT hemoglobin ≥ 12 g/dl (RR 1.88; p = 0.018), T category T1-T2 (RR 2.72; p < 0.001), and surgery (RR 2.29; p = 0.007) were significantly associated with improved LRC. PreRT hemoglobin ≥ 12 g/dl (RR 1.98; p = 0.040) and T category T1-T2 (RR 3.33; p < 0.001) were significantly associated with improved MFS. Positive HPV status (RR 2.19; p = 0.019), pre-RT hemoglobin ≥ 12 g/dl (RR 2.15; p = 0.002), T category T1-T2 (RR 2.31; p = 0.002), and AJCC stage III (RR 1.91; p = 0.034) were significantly associated with improved OS. CONCLUSION: Improved treatment outcomes were significantly associated with positive HPV status, better performance status, lower tumor stage, and pretreatment hemoglobin levels ≥ 12 g/dl. These factors should be considered in future trials.
BACKGROUND AND PURPOSE: The prognosis of patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) is generally poor. However, prognostic factors can help optimize the care for the individual patient. This study investigated potential prognostic factors, including HPV status, for locoregional control (LRC), metastases-free survival (MFS), and survival (OS). PATIENTS AND METHODS: Twelve potential prognostic factors were investigated in 170 patients irradiated for stage III or IV SCCHN, including age (≤ 60 vs > 60 years), gender, ECOG performance score (0-1 vs 2), preradiotherapy hemoglobin level (< 12 vs ≥ 12 g/dl), tumor site (oropharynx, oral cavity, hypopharynx, or larynx), histological grade (G1-2 vs G3), T category (T1-T2 vs T3-T4), N category (N0-N1 vs N2-N3), AJCC stage (III vs IV), surgery (no vs yes), and chemotherapy (no vs yes). RESULTS: On multivariate analysis, positive HPV status (RR 2.34; p = 0.014), ECOG performance score 0-1 (RR 1.94; p = 0.017), preRT hemoglobin ≥ 12 g/dl (RR 1.88; p = 0.018), T category T1-T2 (RR 2.72; p < 0.001), and surgery (RR 2.29; p = 0.007) were significantly associated with improved LRC. PreRT hemoglobin ≥ 12 g/dl (RR 1.98; p = 0.040) and T category T1-T2 (RR 3.33; p < 0.001) were significantly associated with improved MFS. Positive HPV status (RR 2.19; p = 0.019), pre-RT hemoglobin ≥ 12 g/dl (RR 2.15; p = 0.002), T category T1-T2 (RR 2.31; p = 0.002), and AJCC stage III (RR 1.91; p = 0.034) were significantly associated with improved OS. CONCLUSION: Improved treatment outcomes were significantly associated with positive HPV status, better performance status, lower tumor stage, and pretreatment hemoglobin levels ≥ 12 g/dl. These factors should be considered in future trials.
Authors: Markus Stock; Wolfgang Dörr; Carmen Stromberger; Ulrike Mock; Susanne Koizar; Richard Pötter; Dietmar Georg Journal: Strahlenther Onkol Date: 2010-11-30 Impact factor: 3.621
Authors: Hendrik Andreas Wolff; Jan Bosch; Klaus Jung; Tobias Overbeck; Steffen Hennies; Christoph Matthias; Clemens F Hess; Ralph M Roedel; Hans Christiansen Journal: Strahlenther Onkol Date: 2010-04-26 Impact factor: 3.621
Authors: A Becker; P Stadler; R S Lavey; G Hänsgen; T Kuhnt; C Lautenschläger; H J Feldmann; M Molls; J Dunst Journal: Int J Radiat Oncol Biol Phys Date: 2000-01-15 Impact factor: 7.038
Authors: Ervinna Pang; Naomi C Delic; Angela Hong; Mei Zhang; Barbara R Rose; J Guy Lyons Journal: Int J Radiat Oncol Biol Phys Date: 2010-11-23 Impact factor: 7.038
Authors: Carole Fakhry; William H Westra; Sigui Li; Anthony Cmelak; John A Ridge; Harlan Pinto; Arlene Forastiere; Maura L Gillison Journal: J Natl Cancer Inst Date: 2008-02-12 Impact factor: 13.506
Authors: S A Leibel; C B Scott; M Mohiuddin; V A Marcial; L R Coia; L W Davis; Z Fuks Journal: Int J Radiat Oncol Biol Phys Date: 1991-08 Impact factor: 7.038
Authors: Anjali K Gupta; John H Lee; Werner W Wilke; Harry Quon; Gareth Smith; Amit Maity; John M Buatti; Douglas R Spitz Journal: Int J Radiat Oncol Biol Phys Date: 2009-07-01 Impact factor: 7.038
Authors: A K Due; I R Vogelius; M C Aznar; S M Bentzen; A K Berthelsen; S S Korreman; C A Kristensen; L Specht Journal: Strahlenther Onkol Date: 2012-05-13 Impact factor: 3.621
Authors: S Tribius; J Sommer; C Prosch; A Bajrovic; A Muenscher; M Blessmann; A Kruell; C Petersen; M Todorovic; P Tennstedt Journal: Strahlenther Onkol Date: 2013-01-27 Impact factor: 3.621